T. Rowe Price Associates
CLOV icon

T. Rowe Price Associates’s Clover Health Investments CLOV Stock Holding History

T. Rowe Price Associates’s Portfolio CLOV Stock Details CLOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.54M Buy
484,893
+81,992
+20% +$278K ﹤0.01% 1894
2026
Q1 		$710K Buy
402,901
+67,377
+20% +$146K ﹤0.01% 2302
2025
Q4 		$789K Sell
335,524
-33,305
-9% -$91K ﹤0.01% 2181
2025
Q3 		$1.13M Buy
368,829
+18,570
+5% +$53K ﹤0.01% 2002
2025
Q2 		$978K Buy
350,259
+197,759
+130% +$650K ﹤0.01% 1998
2025
Q1 		$548K Buy
+152,500
New +$612K ﹤0.01% 2217
2023
Q2 		– Sell
-69,854
Closed -$60K – 2901
2023
Q1 		$60K Sell
69,854
-153,349
-69% -$168K ﹤0.01% 2768
2022
Q4 		$207K Buy
223,203
+5,269
+2% +$7.03K ﹤0.01% 2517
2022
Q3 		$371K Buy
217,934
+81,834
+60% +$214K ﹤0.01% 2276
2022
Q2 		$291K Buy
136,100
+57,605
+73% +$153K ﹤0.01% 2452
2022
Q1 		$279K Buy
78,495
+32,178
+69% +$93.3K ﹤0.01% 2578
2021
Q4 		$172K Buy
46,317
+21,745
+88% +$133K ﹤0.01% 2790
2021
Q3 		$182K Buy
+24,572
New +$210K ﹤0.01% 2747

Other funds holding CLOV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

T. Rowe Price Associates's CLOV Position: Q2 2026 in Review

T. Rowe Price Associates increased its Clover Health Investments (CLOV) stake by 20% in Q2 2026, buying an estimated $278K and bringing the position to 484,893 shares worth $2.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1894.

T. Rowe Price Associates first reported a position in CLOV in Q3 2021 and has held it in 13 quarters since. 227 funds tracked by Wall St. Rank hold CLOV as of Q2 2026.

  • T. Rowe Price Associates held 484,893 shares of Clover Health Investments worth $2.54M as of Q2 2026.
  • T. Rowe Price Associates bought 81,992 Clover Health Investments shares in Q2 2026, an estimated $278K.
  • Clover Health Investments made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1894 holding.
  • T. Rowe Price Associates first reported a position in Clover Health Investments in Q3 2021 and has held it in 13 quarters since.
  • 227 funds tracked by Wall St. Rank held Clover Health Investments as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.